Kenya could pull out of this year's Rio Olympics due to concerns over the Zika virus outbreak in Brazil, the head of Kenya's Olympics committee said.» Read More
After the closing bell Monday, Eli Lilly and Amylin Pharmaceuticals announced that they're going to hold a conference call for analysts and investors about their diabetes drug Byetta. Why?
Stanford University, concerned about the influence drug companies may have on medical education, is expected to announce Tuesday that it will severely restrict industry financing of doctors’ continuing education at its medical school, according to the New York Times.
Talk about timely direct-to-consumer advertising. Last week ,I blogged about AstraZeneca's new ad campaign for FluMist and its tie-in with the back-to-school shopping season. Well, now the drugmaker is getting political.
As we head into my last free summer weekend before USC's football season kicks off, I wanted to clean out the Pharma's Market mailbox. (Actually I was looking for an apropos-of-nothing excuse to mention the Trojans.)
Shares of Genentech are taking another little breather after rising to around 99 bucks on speculation that a higher offer is coming from Roche. Analyst guestimates of the ultimate takeout price -- if, indeed there is one -- are generally above a hundred dollars a share.
Two prominent articles in a major medical journal are examining the cost benefits and safety of an expensive, controversial vaccine for a sexually-transmitted disease and cancer.
Gerald Jordan, portfolio manager at Jordan Opportunity Fund said that investing in large cap stocks is the way to go.
A photographer for the "New York Post" snapped this picture last night of a nattily dressed Sam Waksal returning to a halfway house in the Bronx after going on a little shopping trip.
It was my turn to man the CNBC Alerts Desk earlier today from 9am ET to 1 pm ET. I had finished blogging about the "Barron's bounce" Amylin Pharmaceuticals was getting, based on the speculative mention about it being a potential takeout target for Eli Lilly. Then, I look up at the screen and see AMLN is absolutely tanking...
U.S. health regulators are seeking stronger warnings about the risk of pancreatitis after the deaths of two patients taking Amylin Pharmaceuticals' injectable diabetes drug Byetta, sending the company's shares down as much 16 percent.
Ads for flu vaccines have traditionally been confined to PSAs, health and media alerts. So that's why I was surprised to see this colorful full-page ad in The New York Times this weekend for FluMist from AstraZeneca/MedImmune. Why..?
Late last week I blogged that ImClone Systems founder and former CEO Sam Waksal was, according to a source, going to get out of a federal prison in Michigan and move into a halfway house in the Bronx between August 7th and the 14th.
This is how you balance Mad Money stock picks with your own portfolio.
This biotech sells its treatment to a niche clientele for big money.
Biotechnology company ImClone Systems, which rebuffed a $60-per-share takeover offer from Bristol-Myers Squibb, said on Thursday it hired JP Morgan Chase as its financialadviser.
The market cap of Dow component Johnson & Johnson is a whopping $200 billion. Abbott Labs is valued at less than half that. But think of ABT as kind of a mini-me JNJ because like Johnson & Johnson, ABT has cobbled together a similar three-siloed business of drugs, devices and consumer products.
Vertex Pharma is lagging its peers. But biotech is so good right now, it might not matter.
A new study and an editorial in a major medical journal could reignite the debate over whether drugs or stents or a combination of both are better for the millions of Americans with heart trouble.
Before I get to my favorite biotech saga, there are noteworthy, if not newsworthy, press releases out this morning from two takeout targets. Genentech put out a statement from the special independent board committee that's been appointed to handle the Roche buyout offer.
Genzyme may make orphan drugs, but this company is a lot closer to Daddy Warbucks.